Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $81

Benzinga Newsdesk www.benzinga.com Positive 87.5%

Neg 0% Neu 0% Pos 87.5%

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $69 to $81.